, and c-Kit). 7, 8 Their presence in peripheral blood has been well correlated with PAH in a number of studies, [9] [10] [11] [12] and BM-derived cells with endothelial or progenitor cell markers have been identified in the walls of remodeled vessels from PAH patients. 10, 13, 14 Although PACs are not thought to proliferate and occlude pulmonary vessels themselves, they are hypothesized to promote pathological vasculogenic-like processes in neighboring endovascular cells. 15 However, their exact function remains obscure, and to date, no study has definitively established their role in promoting (or abrogating) disease.
The molecular mechanisms governing PAC function in disease are equally opaque. Signaling through the 5-HT 2B (serotonin 2B receptor), responsible for mediating serotonergic diet drug-induced PAH in humans, 16 is also necessary for the myeloid contribution to experimental pulmonary hypertension (PH) in hypoxic mice. 17 Mice lacking 5-HT 2B have similar metrics of hematopoiesis to wild-type animals with a notable exception of fewer CD31 + CD11b
− cells in the BM and peripheral circulation, identified as immature proangiogenic or endothelial-like cells. It is possible that intact 5-HT 2B signaling may be necessary for PAC recruitment or function.
We hypothesized that PACs contribute directly to smallvessel stiffening and remodeling through a 5-HT 2B -dependent mechanism. By selectively ablating PACs using a transgenic mouse model, we successfully prevent and reverse the development of elevated pulmonary pressures after hypoxia exposure and enhanced endovascular injury with SU5416. PAC ablation also reduced markers of small-vessel remodeling and restored vessel wall compliance to normal levels. We then illustrate the effectiveness of 5-HT 2B antagonism in preventing experimental PH in the same disease model and, through lineage tracing of hematopoietic cells, show reduced recruitment and altered gene expression profiles of PACs in animals treated with a pharmacological inhibitor of 5-HT 2B . Finally, we show that PACs enhance pulmonary microvascular endothelial injury response in vitro and that stiffened arterioles in human lungs with PAH correlate with the presence of PACs. Our data indicate that BM-derived PACs are necessary for the development of experimental PH in the setting of endovascular injury and likely contribute to small artery stiffening and remodeling.
Methods
The authors declare that all supporting data are available within the article [and its files in the Online Data Supplement].
BM Transplantation and Transgenic Mouse Models
All mouse experiments were approved by the Vanderbilt Institutional Animal Care and Use Committee before their initiation. Six-to 12-week-old C57BL/6 mice were given a split 12 Gy dose of radiation from a Cs 137 source followed by retro-orbital administration of 5×10 5 BM cells isolated from an age-and sex-matched cogenic donor. Male mice were used to control for the well-documented effects 
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Novelty and Significance
What Is Known?
• Pulmonary hypertension (PH) is a deadly, incurable disease in which the pulmonary vasculature is slowly obliterated through a process of active endovascular remodeling.
• Bone marrow-derived proangiogenic cells (PACs) are a heterogeneous subpopulation of myeloid-derived cells previously observed in the walls of remodeling vessels in human and experimental PH.
• Intact signaling from the 5-HT 2B (serotonin 2B receptor) in bone marrow cells is necessary for the development of experimental PH, and pharmacological inhibition of 5-HT 2B reduces the number of PACs in the peripheral blood of mice.
What New Information Does This Article Contribute?
• Using a transgenic chimeric animal model in which we selectively destroy PACs, we show that PACs directly contribute to experimental PH in mice.
• We also show that 5-HT 2B inhibition prevents experimental PH, reduces the number of PACs in the lungs of mice with experimental PH, and alters the function of PACs in vivo.
PH is a deadly illness with no cure and a poorly understood pathogenesis. Bone marrow-derived PACs are correlated with disease severity and arteriole remodeling in PH, but their exact function (for good or ill) and the signaling mechanisms regulating their contribution to illness remains poorly understood. By selectively destroying PACs from the bone marrow of mice, we prevent and reverse existing experimental PH induced by a combination of endovascular injury and hypoxia. We also identify the ). Transplants were again performed as described.
Induction of Experimental PH and Hemodynamic Phenotyping
To induce experimental PH with enhanced endovascular injury, we administered the VEGFR2 inhibitor SU5416 (Tocris Biosciences) at 20 mg kg −1 wk −1 intraperitoneally while maintaining mice in hypoxia (10% O 2 ) for 3 weeks. Also referred to as the Sugen-hypoxia model of experimental PH, inhibition of VEGFR2 in combination with hypoxia results in hypoxic vascular injury and a proliferative vascular remodeling response mimicking human PAH pathology 21 that persists up to 10 weeks after the secession of hypoxia and SU5416. 22 Animals exposed to hypoxia alone received vehicle injections (0.5% carboxymethylcellulose, 0.4% polysorbate, 0.9% benzyl alcohol [Sigma-Aldrich] in 0.9% sterile saline). Control animals were exposed to room air while receiving either SU5416 or vehicle injections. For randomization, mice were given an identification number with no relation to experimental group assignment before disease induction. To ablate BM-derived PACs, SCL-Cre ) or vehicle (50% dimethyl sulfoxide [Sigma-Aldrich] and polyethylene glycol-400 [Fisher Chemical]) 24 hours before disease induction. After 3 weeks, mice were placed under surgical anesthesia (Avertin), and a catheter was inserted into the right heart via the right jugular vein in a closed-chest procedure to measure right ventricular systolic pressures (RVSPs), as previously described. 23 All mice that were alive at the conclusion of the procedure were included in data analysis. Mice were euthanized with phenobarbital before collection of biologic samples.
Immunohistochemistry
Lungs were isolated, flushed with PBS, inflated and embedded with optimal cutting temperature compound, flash frozen in liquid nitrogen, and sectioned. Before staining, lung sections were fixed in a solution of 4% paraformaldehyde (Electron Microscopy Sciences) and 0.01% Triton in PBS. Sections were stained with FITC (fluorescein isothiocyanate)-conjugated rat anti-mouse CD31 (CD31-FITC; BD Biosciences, catalog No. 558738), Cy3-conjugated mouse monoclonal anti-α-SMA (α-smooth muscle actin; α-SMA-Cy3; Sigma-Aldrich, SKU C6198), and DAPI (Thermo Fisher Scientific). Lung sections from Tie2-Cre/YFP fl/− transplanted animals were also stained with AF647-conjugated anti-GFP (GFP-AF647; Thermo Fisher Scientific, catalog No. A-31852). Control specimens included unstained slides. Slides were labeled only with randomized animal identification number, and data acquisition was performed without knowledge of the treatment group. The number of fully (>75% of vessel circumference) and partially muscularized α-SMA-positive pulmonary arterioles (<100 μm diameter) was quantified from images taken using an Olympus microscope. In lung sections taken from Tie2-Cre/YFP fl/− transplanted animals, pulmonary arterioles were further evaluated for the presence of cells expressing both YFP and CD31, identified as PACs (negative controls shown in Online Figure I ).
Measurement of Pulmonary Arteriole Wall Elastic Modulus
Atomic force microscopy (AFM) of whole tissue sections was performed based on previously described methods. 24, 25 Fresh-frozen lung sections 10 μm thick were stained with anti-mouse CD31 (BD Biosciences; catalog No. 557355), FITC-conjugated anti-rat IgG secondary (BD Biosciences; catalog No. 554016), α-SMA-Cy3, and DAPI. Lung sections from Tie2-Cre/YFP fl/− transplanted animals were also stained with anti-GFP (green florescent protein)-AF647. Control specimens included unstained and FITC-conjugated antirat secondary only. After staining, sections were immersed in PBS, and α-SMA-positive vessels <100 μm in diameter were identified using a Nikon Eclipse Ti microscope. Vessels were then scanned using a Bioscope Catalyst AFM at a scanning frequency of 0.25 Hz and a scan window size of 5 to 8 μm. Slides were labeled only with randomized animal identification number, and data acquisition was performed without knowledge of the treatment group. A total of 12 to 32 vessels were scanned for each animal, across 
Flow Cytometric Characterization
Lung cells were obtained from digesting masticated lungs in a solution of 5% fetal bovine serum, 1 mg/mL collagenase type IV, and 0.02 mg/mL DNase I (Sigma-Aldrich) in RPMI 1640 (Roswell Park Memorial Institute medium) for 45 minutes at 37°C. Peripheral blood mononucleocytes (PBMCs) were isolated from blood drawn from the right jugular. Red blood cells were lysed using red blood cell lysis buffer (BioLegend). For quantifying the number of PACs in the lungs and peripheral blood, both PBMCs and lung cells were stained with anti-Ter119-Pacific Blue, CD11b-redFluor (Tonbo Biosciences; catalog No. 10141-234 and No. 80-0112), CD31-PECy7 (BioLegend; catalog No. 102524), and DAPI. To quantify engraftment, PBMCs were stained with anti-Ter119-Pacific Blue, CD45.1-PE (BD Biosciences; catalog No. 561872), CD45.2-PerCPCy5.5 (Tonbo Biosciences; catalog No. 65-0454), and DAPI. Flow cytometry was performed using a BD LSR Fortessa and the data analyzed using FlowJo. Antibodyconjugated beads (Thermo Fisher) were used for single stain compensation controls. Unstained cells and fluorescence minus one controls were used for gating populations in all flow cytometry experiments.
Electric Cell-Substrate Impedance Sensing in Microvascular Endothelial Cells
For in vitro electric cell-substrate impedance sensing experiments, mouse pulmonary microvascular endothelial cells (PMVECs) were seeded in electric cell-substrate impedance sensing well plates (8W1E for electroporation wounding; Applied Biophysics) at a density of 150 000 per well. After 2 hours of baseline measurements, a wound was applied to the entire plate surface (250 μm diameter) by administering a 60 kHz pulse for 20 s, and the treatments were added to wells in duplicate. Treatments included (1) blank controls or 10 000 PACs isolated from the lungs of mice with experimental PH, as described; (2) dimethyl sulfoxide or 1 μg/mL SB204741; or (3) 10 000 PACs with dimethyl sulfoxide or 1 μg/mL SB204741. Measurements were taken on a single channel at 4 kHz for 24 hours using the electric cell-substrate impedance sensing ZTheta (Applied Biophysics). Data were normalized to values at the time the wound was applied and treatment added.
RNA Sequencing and Analysis
Adult male C57BL/6 mice were maintained on vehicle for SB204741 in normoxia for 3 weeks as described after which BM cells and PBMCs were collected. BM cells and PBMCs were stained with anti-Ter119-, Gr1-, B220-, and CD3-PacificBlue (Tonbo Biosciences; 
CD11b
− cells were sorted using a BD FACSAria III and collected in PBS (>95% purity). A Qiagen RNeasy Micro kit was used for RNA isolation. mRNA enrichment, cDNA library preparation, and sequencing were performed by the Vanderbilt Technologies for Advanced Genomics center.
Analysis of RNA-seq data was performed using the Amazon Elastic Compute Cloud. Standard quality control analyses on raw reads were done using FastQC v 0.11.5, with quality trimming and adaptor removal performed using Trimmomatic v 0.36 and read alignment performed using STAR v 2.5.2b. Raw read counts were normalized using the TMM (trimmed mean of M-values) method of library size normalization in edgeR, and differential expression was performed in limma (Bioconductor v3.3). RNA sequencing data will be made publicly available through the National Center for Biotechnology Information Gene Expression Omnibus repository.
Differentially expressed genes (P<0.01) were selected for inclusion in the gene ontology (GO) enrichment analysis. A GO slim analysis was performed using the BinGO app in Cytoscape, with GO annotation files downloaded from the GO consortium. [26] [27] [28] GO enrichment analysis for GO biologic processes was performed using the Web-based GEne SeT AnaLysis Toolkit (WebGestalt). 29 Significantly enriched GO terms are defined as having a P <0.05 after a false discovery rate correction.
Statistical Analysis
Statistical analysis was performed using SigmaPlot version 11 and the R programming language. The Shapiro-Wilk test was used to test for data normality. Data were subsequently analyzed using either a 2-way ANOVA with Holm-Sidak post hoc test or a Kruskal-Wallis rank-sum test with Conover-Iman post hoc test for nonparametric data. A 2-tailed Student t test was used for single comparisons of 2 normally distributed groups. Data were considered significantly different for P <0.05.
Results
Ablation of PACs Prevents Experimental PH and Normalizes Metrics of Pulmonary Vascular Remodeling
To determine whether BM-derived PACs contributed to the development of experimental PH, we used a chimeric mouse model that would allow us to selectively ablate hematopoietic cells with a uniquely endothelial genetic signature. These mice, developed previously to study the contribution of hematopoietic PACs to tumor endothelium, display little to no expression of Cre in hematopoietic stem cells (as opposed to their 3′-SCL counterparts), making them an ideal lineagerestricted driver strain. 19 After transplant and reconstitution (Online Figure II) , mice were placed in either hypoxia with weekly SU5416 injections to induce experimental PH or normoxia and received either vehicle or tamoxifen injections for 3 weeks ( Figure 1A ). After right heart catheterization, mice receiving tamoxifen for PAC ablation were found to have significantly lower pressures than their vehicle-treated counterparts ( Figure 1B) , though no effect on RV hypertrophy was observed ( Figure 1C ). The number of muscularized small arteries was increased in vehicle-treated mice after hypoxic vascular injury, with PAC ablation significantly reducing the number of fully, but not partially, muscularized arteries ( Figure 1D and 1E) . As stiffening of the distal pulmonary vasculature is an early event in experimental PH and important in the potentiation of further vascular remodeling, 3 ,4,30 we next assessed whether PAC ablation altered pulmonary arteriole stiffness. Using AFM, we found that vehicle-treated animals exposed to hypoxia and SU5416 had significantly stiffer pulmonary arterioles, as we and others have previously reported for other mouse models of PAH using this same technique, 3, 25 and that ablation of BM-derived PACs normalized vessel stiffness ( Figure 1F through 1H) . In mice exposed to hypoxia-alone, tamoxifen treatment failed to reduce RVSP, vessel muscularization, or arteriole stiffness. Furthermore, significantly fewer muscularized arterioles were observed in these mice compared with hypoxia-and SU5416-exposed animals.
( Figure 1B through 1F) , suggesting that PAC-mediated effects occur only in the setting of SU5416-mediated endovascular injury. Tamoxifen treatment also failed to reduce elevated RVSP in mice transplanted with BM from mice expressing SCL-Cre ERT2 but not the inducible diphtheria toxin gene, illustrating that diphtheria toxin expression and subsequent ablation of PACs is necessary for PH prevention (Online Figure  III) . The observed effects of PAC ablation are unlikely because of alterations in inflammatory cell populations, as flow cytometric characterization of PBMCs performed on mice with BM from endothelial SCL-Cre 
Pharmacological Inhibition of 5-HT 2B Prevents Experimental PH and Vascular Remodeling
We next tested the hypothesis that 5-HT 2B signaling mediated the recruitment or function of BM-derived PACs to the lungs during experimental PH. To perform lineage tracing on PACs, we used mice expressing both a Tie2 promoterdriven Cre and a ROSA26 promoter-driven fluorescent reporter (YFP) proceeded by a loxP-flanked STOP codon as BM donors. As Tie2 is expressed on hematopoietic stem cells, this model allowed us to positively identify all BM cells regardless of lineage. 20 We combined this approach with cell surface labeling of CD31 + CD11b − BM-derived cells, a cell population containing PACs and reportedly reduced in number in 5-HT 2B -deficient mice. 17 This strategy allowed us to determine how 5-HT 2B antagonism alters the recruitment of multiple inflammatory cell lineages, including BM-derived PACs, during experimental PH (Online Figure V) . Both engraftment efficiency and the efficiency of Cre-mediated recombination were comparable regardless of treatment, with the majority (>80%) of donor CD45.2 + lymphocytes expressing YFP (Online Figure VI) . After transplantation and reconstitution, the mice were placed in either normoxia or hypoxia and subcutaneously implanted with an osmotic pump delivering the 5-HT 2B antagonist SB204741 or vehicle for 3 weeks (Figure 2A ). Pharmacological inhibition of 5-HT 2B with SB204741 was sufficient to normalize RVSP as measured by right heart catheterization compared with vehicle-treated controls ( Figure 2B ), though it had no effect on RV remodeling ( Figure 2C ). Treatment with SB204741 also reduced the number of fully (but not partially) muscularized arterioles ( Figure 2D ). Measurements of pulmonary arteriole wall elastic modulus with AFM show a significant reduction in vascular stiffness after SB204741 treatment in mice exposed to hypoxia and SU5416 ( Figure 2F through 2H) , recapitulating the results we observed when ablating PACs. Also similar to PAC ablation, SB204741 treatment failed to normalize RVSP, vessel muscularization, and arteriole stiffness in mice exposed to hypoxia in the absence of SU5416 (Figure 2B through 2F) .
5-HT 2B Antagonism Reduces the Fraction and Alters the Activity of BM-Derived PACs During Experimental PH
We next quantified the fraction of PACs in the lungs and peripheral blood after induction of experimental PH with SU5416-enhanced endovascular injury and vehicle or SB204741 treatment. Mice exposed to hypoxia and SU5416 and treated with SB204741 had a significantly reduced fraction of BMderived (YFP + ) PBMCs expressing the endothelial marker CD31 and absent for the immature myeloid marker CD11b (CD31 + CD11b − ) as assessed by flow cytometry ( Figure 3A) . We also observed a small but statistically significant increase in the fraction of YFP + CD31 + CD11b − cells in the lungs of hypoxia-and SU5416-exposed animals compared with controls. This fraction was reduced in mice treated with SB204741 ( Figure 3B ). Importantly, neither hypoxic vascular injury nor SB204741 treatment altered the total number of lung cells present, or the fraction of lung cells that expressed YFP, suggesting the absence of large-scale inflammatory infiltrate. There Figure 1 . Ablation of bone marrow (BM)-derived proangiogenic cells (PACs) reduces elevated right ventricular systolic pressure (RVSP) and inhibits the muscularization and stiffening of pulmonary arterioles in experimental PH with SU5416-enhanced endovascular injury. A, Experimental approach. B, Ablation of BM-derived PACs normalizes RVSP in hypoxia+SU5416-treated animals. This effect is not observed in animals exposed to hypoxia alone. C, PAC ablation has no effect on RV remodeling in either animal model (n=4-6). D, E, Animals exposed to hypoxia+SU5416 have significantly more muscularized arterioles (<100 μm diameter) than animals exposed to hypoxia alone, and PAC ablation significantly reduces the number of fully muscularized arterioles in hypoxia+SU5416 exposed but not in hypoxia-alone exposed animals (n=3). F, Similarly, PAC ablation normalizes arteriole stiffness in animals exposed to hypoxia+SU5416, but not in animals exposed to hypoxia alone (n=3-6). G, Representative modulus distributions and (H) scan windows for individual vessels. B-D, F, Mean±SE, *P<0.05 following (B, C, F) 2-way ANOVA and Holm-Sidak post hoc test or (D) Kruskal-Wallis rank-sum test with Conover-Iman post hoc test. α-SMA indicates α-smooth muscle actin; CMC, carboxymethylcellulose vehicle; HPF, high-powered field; and n.s., not significant.
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was also no significant effect on macrophage recruitment to the lung, another important inflammatory cell type in PAH pathogenesis 31 (Online Figure VIIC through VIIE) . Although BM-derived c-Kit + cells have previously been reported to accumulate in the walls of remodeled vessels and potentially mediate vessel remodeling in a 5-HT 2B -dependent manner, 12, 13, 17 we observed a nonsignificant increase in the fraction of cKit + cell embedded in the vessel wall ( Figure 4A and 4B) . Interestingly, pharmacological antagonism of 5-HT 2B in the absence of hypoxic vascular injury significantly increased the localization of PACs to the Figure 2 . Antagonism of the 5-HT 2B (serotonin 2B receptor) receptor normalizes elevated right ventricular systolic pressure (RVSP) and reduces the muscularization and stiffening of pulmonary arterioles in experimental pulmonary hypertension (PH) with SU5416-enhanced endovascular injury. A, Experimental approach. B, 5-HT 2B antagonist, SB204741, normalizes RVSP in mice exposed to hypoxia+SU5416. This effect is not observed in animals exposed to hypoxia alone. C, SB204741 has no effect on RV remodeling in either animal model (n=7-8). D-E, Animals exposed to hypoxia+SU5416 have significantly more muscularized arterioles (<100 μm diameter) than animals exposed to hypoxia alone, and SB204741 significantly reduces the number of fully muscularized arterioles in hypoxia+SU5416 exposed but not in hypoxia-alone exposed animals (n=3-5). F, SB204741 normalizes arteriole stiffness in animals exposed to hypoxia+SU5416, but not in animals exposed to hypoxia alone (n=3-6). G, Representative modulus distributions and (H) scan windows for individual vessels. B-D, F, Mean ±SE, *P<0.05 following B, C, and F, 2-way ANOVA and Holm-Sidak post hoc test or (D) Kruskal-Wallis rank-sum test with Conover-Iman post hoc test. α-SMA indicates α-smooth muscle actin; CMC, carboxymethylcellulose vehicle; HPF, high-powered field; and n.s., not significant. walls of pulmonary arterioles, while leaving the total fraction of YFP + CD31 + CD11b − cells unchanged (as evidenced by flow cytometry data).
We next assessed whether or not the presence or absence of PACs was correlated with increased vessel wall stiffness. After determining the vessel wall elastic modulus using AFM, we subdivided vessels into either positive or negative for YFP + CD31 + cells in the vessel wall. On average, the measured vessel wall elastic modulus was significantly higher for vessels with at least 1 positively identified YFP + CD31
+ cell in vehicle-treated animals exposed to hypoxia and SU5416 ( Figure 4C and 4D) . Although a significant fraction of vessels in SB204741-treated animals were identified as having >1 YFP + CD31 + vessel, the presence or absence of these cells was not correlated with a significant difference in vessel stiffness in either hypoxic or normoxic conditions.
To determine how 5-HT 2B antagonism might alter the function or phenotype of PACs, we performed RNA sequencing on PACs isolated from mice treated with either vehicle or SB204741 in normoxic conditions (Online Figure VIII) . The results of both a GO slim analysis and full GO Biologic Process analysis for PACs isolated from both BM and peripheral blood were notable for a significant enrichment of genes broadly regulating immunologic processes, cytoskeletal regulation and cell motility, and cell differentiation. A more detailed GO enrichment analysis for all biological process categories indicated that, in PACs isolated from BM, 5-HT 2B antagonism altered phosphorylation events associated with cellular metabolism, processes involved in cell development and differentiation, and cell motility and migration. Contrastingly, in peripheral blood-isolated PACs, genes regulating cytokine production and response, cell motility and migration, and cell division were significantly enriched (Online Figure IX) .
BM-Derived PACs Are Necessary for Maintenance of the Experimental PH Phenotype in Mice
We next sought to determine whether BM-derived PAC presence was necessary for maintaining the PH phenotype. Previous studies employing the same hypoxic vascular injury model of PH illustrate that the combination of SU5416 and hypoxia is sufficient to maintain elevated RVSP in normoxic conditions for up to 10 weeks after the initial induction 22 and has been used previously to study the efficacy of interventions to reverse or hasten the remission of established experimental PH. 32 Adapting our protocol from these previous studies, we induced experimental PH in mice transplanted with BM from endothelial SCL-Cre ERT2 / DTa fl/− donors ( Figure 5A , Online Figure X) . After 3 weeks, we moved the mice to room air for an additional 3 weeks and administered vehicle or tamoxifen to ablate BM-derived PACs. We found that BM-derived PAC ablation significantly reduced RVSP in mice exposed to hypoxia+SU5416 ( Figure 5B ), though no effect on RV remodeling was observed ( Figure 5C ). PAC ablation also reduced the number of muscularized arterioles, though this effect was not statistically significant ( Figure 5D ). Arteriole stiffness remained elevated in vehicle-treated mice after their return to room air but was significantly reduced in mice after BM-derived PAC ablation ( Figure 5E through 5G) .
BM-Derived PACs Isolated From the Lungs of Mice With Experimental PH Promote Endothelial Cell Proliferation, Migration, and Spreading In Vitro
To determine the effect of PACs on PMVECs, we used electric cell-substrate impedance sensing to monitor the recovery of endothelial cell monolayer confluence after injury in the presence or absence of PACs. After induction of experimental PH, BM-derived (CD45
− cells (PACs) were isolated from the lungs (further flow cytometric characterization in Online Figure XI shows that this cell population excludes major inflammatory cell groups, including T and B cells). After injury, PMVECs cocultured with PACs demonstrated enhanced resistance at t 1/2 =11 hours and enhanced impedance and reduced capacitance at both 11 and 22 hours ( Figure 6A ). These measurements correspond directly to cell barrier quality (resistance) and cell spreading and migration (capacitance) or both (impedance). We repeated this experiment on PMVECs cultured in the presence of SB204741 or vehicle and found that the drug did not alter PMVEC barrier quality, spreading, + cell. Conversely, SB204741 treatment significantly increased both of these metrics in the absence of hypoxic vascular injury (n=3-4, mean±SE, *P<0.05 following 2-way ANOVA with Holm-Sidak post hoc test). C, D, In normoxic and SU5416+hypoxia-treated animals, arterioles with at least 1 adjacent BM-derived CD31 + cell were significantly stiffer than those without adjacent BM-derived CD31 + cells. In either case, SB204741 treatment normalized the stiffness of the vessel walls (n=5-14, mean±SE, *P<0.05 after 2-tailed Student t test).
or migration ( Figure 6B) . Interestingly, the drug also failed to appreciably alter these same quantities in PMVECs cultured with PACs ( Figure 6C ), suggesting that 5-HT 2B inhibition may be working further upstream to inhibit the pathogenic effect of PACs, perhaps at the point of cell differentiation or proliferation in the myeloid compartment.
BM-Derived CD31 + Cell Presence Correlates With Stiffer Arterioles in the Lungs of Human PAH Patients
After establishing that BM-derived PACs are necessary for both initiation and maintenance of the experimental PH phenotype in mice, we next sought to establish whether the presence of an analogous cell in humans might also correlate with remodeled and stiffened pulmonary arterioles. We performed AFM on pulmonary arterioles identified from lung sections taken from a small cohort of patients with either idiopathic or hereditary PAH (Online Table I ). Costaining with α-SMA, CD31, and the hematopoietic marker CD45 allowed us to identify pulmonary arterioles with at least 1 adjacent BM-derived CD31 expressing cell (CD45 + CD31 + ). On scanning these vessels, we found them to be significantly stiffer on average than vessels lacking an adjacent CD45 + CD31 + cell, recapitulating our results from the animal experiments ( Figure 7) .
Discussion
By using a combination of genetically targeted ablation and pharmacological inhibition, we have illustrated that BMderived PACs contribute directly to experimental PH in the setting of enhanced endovascular injury and that the 5-HT 2B receptor is a critical mediator of this contribution. Prior evidence for PAC involvement in vascular remodeling is primarily derived from observations that BM-derived cells expressing endothelial or progenitor surface markers accumulate in the walls of remodeled arterioles 13, 14, 33 and that increased or decreased numbers of these cells are found in the peripheral blood of PAH patients (depending on the surface markers used for identification or the patient cohort studied). [34] [35] [36] Pharmacological blockade of c-Kit 17 and the chemokine receptors CXCR4 and CXCR7 12, 37 has been successful in preventing experimental PH presumably by targeting subsets of this cell population, but the ubiquity of chemokine receptor expression among hematopoietic cell types (as well as native vascular endothelium) 38 and lack of specificity among tyrosine kinase receptor antagonists makes interpretation of these results difficult.
Using an inducible endothelial-specific Cre developed for studying hematopoietic PACs 19 allowed us to circumvent the problem of surface marker heterogeneity. By specifically targeting all BM-derived cells with this endothelial phenotype for destruction, we both prevented the development of experimental PH and reversed established illness. Notably, both PAC ablation and 5-HT 2B antagonism were only efficacious in animals exposed to both hypoxia and SU5416, suggesting that PAC function is closely related to the endothelial cell injury response. RV remodeling is reportedly modest for both the hypoxia-alone and hypoxia+SU5416 mouse models, 39 and the success of both interventions in reducing RVSP and while failing to impact RV hypertrophy suggests that they were primarily targeted to the pulmonary microvasculature. The normalization of arteriole compliance after PAC ablation is particularly notable, especially considering the important role that arteriole stiffening plays in experimental PH and PAH pathogenesis. Recent evidence from mouse models and human patients suggests that small-vessel stiffening is an early and perhaps initiating event in experimental PH and PAH. 3 In hypoxia-driven experimental PH, lysyl oxidase ) cells expressing the endothelial marker CD31 predicts pulmonary arteriole stiffening in lungs from a cohort of pulmonary arterial hypertension (PAH) patients. A, Sections of human lung taken from PAH patients were costained for α-SMA (α-smooth muscle actin) to identify pulmonary arterioles (<100 μm in diameter) and CD45 and CD31 to identify BM-derived PACs. Pulmonary arterioles with at least 1 adjacent CD45 + CD31 + cell were on average significantly stiffer than those with no identified CD45 + CD31 + cell (n=25-32, mean±SE, **P<0.01 after 2-tailed Student t test). B, Representative modulus distributions and (C) scan windows for individual vessels. induced crosslinking of collagen occurring within minutes to hours, and inhibition of lysyl oxidases is sufficient to prevent disease onset. 40 Stiffer substrates induce metabolic reprogramming in native endothelial and smooth muscle cells, facilitating their transition to the proliferative and synthetic phenotype that predominates during active vascular remodeling. 4, 30 It is possible that PACs may be the cell type mediating this transition by helping to directly modulate vascular stiffness.
5-HT 2B has long been recognized as a significant contributor to PAH pathogenesis, and more recently as an indispensable mediator of the hematopoietic contribution to disease. 16, 17 We have previously shown that pharmacological blockade of 5-HT 2B is effective in preventing familial experimental PH using a genetic mouse model and that 5-HT 2B antagonism significantly normalizes the expression of genes regulating cytoskeletal maintenance and contractility in the lung. 25 Our results in the current study suggest that this effect may be secondary to the recruitment of PACs after hypoxic vascular injury. 5-HT 2B antagonism exerted similar effects on the PAH phenotype to PAC ablation, effectively normalizing RVSP and metrics of pulmonary vessel remodeling (including vascular stiffness). 5-HT 2B antagonism also altered the fraction of CD31 +
CD11b
− BM-derived cells in circulation and in lung tissue during experimental PH, a cell population with enriched proangiogenic potential, and previously reported to be reduced in the peripheral blood of 5-HT 2B knockout mice. 17, 41, 42 This dual effect suggests that the 5-HT 2B antagonist may be exerting its effects in the BM compartment by preventing the proliferation or differentiation of PACs from a precursor population. The results from our GO enrichment analysis complement these findings, indicating a significant alteration in genes regulating both cell differentiation and proliferation in BM-isolated and peripheral blood-isolated PACs. This hypothesis is consistent with the previously published data showing that 5-HT 2B promotes myeloerythroid differentiation potential in mouse and human hematopoietic stem cells. 17 Furthermore, our observation that 5-HT 2B antagonism fails to inhibit PAC-enhanced PMVEC injury response in vitro also suggests that 5-HT 2B antagonism in vivo alters PAC number or function prior to de-marginalization in the lungs.
Also consistent with previous studies was our observation that CD31 + BM-derived cells accumulate in the walls of muscularized arterioles during experimental PH. 10, 14, 43 We observed that vessels with at least 1 associated BM-derived CD31 + cell were significantly stiffer in both normoxic and hypertensive animals. We observed a similar correlation in PAH patient lungs, suggesting that BM-derived PACs may also mediate small-vessel stiffening and remodeling in human illness. However, these results should be interpreted cautiously, as the limited number of cell surface markers used for characterization and inherent heterogeneity of the cell population in question may confound the analysis, and it is unclear whether these cells are the same population as those ablated in our mouse model.
In mice 5-HT 2B antagonism reduced both the localization of CD31 + BM-derived cells to the walls of remodeling arterioles and the stiffness of vessels with associated CD31 + BM-derived cells. Surprisingly, in the absence of hypoxic vascular injury, we found increased localization of these cells secondary to 5-HT 2B antagonist treatment, despite the absence of observable changes in the total fraction of these cells as measured by flow cytometry. Despite this apparent increase in localization during normoxia, the normalization of vessel wall stiffness suggests that 5-HT 2B antagonism also exerts direct, functional effects on this cell population, impairing their ability to induce vascular remodeling. Our GO enrichment results support this conclusion by showing alterations in cytokine production and signaling pathways secondary to 5-HT 2B antagonism, the hypothesized mechanism whereby PACs contribute to vessel remodeling. 15 There are several important limitations to our study that must be addressed. First, our utilization of transgenic tools necessitated a reliance on the mouse model of endovascular injury, rather than the rat model (which produces a more robust phenotype). The modest phenotype observed in mice makes subtler changes more difficult to detect and does not reproduce all aspects of human disease, and findings must be cautiously interpreted. In addition, our reliance on systemic inhibition of the 5-HT 2B receptor precludes a more precise understanding of its role in mediating BM-derived PAC recruitment and function. 5-HT 2B is expressed in both BM and native pulmonary vascular endothelium, 16, 17 and it is unclear whether the observed effects on PAC recruitment and function were downstream of some other signaling event.
Development of an animal model allowing targeted genetic ablation of the 5-HT 2B receptor from PACs would more precisely elucidate its role in their biology and contribution to illness. This being said, our in vitro data suggest that 5-HT 2B antagonism does not directly alter the interaction between PACs and injured pulmonary microvascular endothelium, nor does it promote alterations in endothelium itself in response to vascular injury. Therefore, it is reasonable to conclude that 5-HT 2B signaling inhibits PAC function or reduces PAC number before their recruitment to the lungs.
The stiffening and muscularization of peripheral arterioles is a complex process involving numerous cell types. Exactly how BM-derived PACs promote and maintain this process remains unclear. Although it is unlikely that these cells themselves proliferate and contribute to vessel muscularization, it is possible that they may in some fashion signal to native endovascular cells promoting the process of vessel remodeling. Our in vitro data show that PACs directly enhance endothelial cell spreading, migration, and barrier quality, the latter of which is also a function of cell proliferation. These effects are observed in the context of vascular injury (consistent with our animal model) and could represent a pathologically enhanced injury response mechanism, whereby endothelial cells respond inappropriately to noxious stimuli.
In the present study, we have illustrated that PACs are indispensable for both the development and maintenance of the experimental PH phenotype and strongly correlate with the presence of stiffened and muscularized pulmonary arterioles. By implicating the 5-HT 2B receptor as a critical mediator of the recruitment and function of these cells during hypoxic vascular injury, we have further defined the function of 5-HT 2B signaling in experimental PH. This discovery provides additional impetus to pursue pharmacological targeting of 5-HT 2B as a potential therapy for PAH and encourages further exploration of PAC function in vascular remodeling in the hopes of identifying novel molecular mediators of illness.
